RG7795
ObjectMedications
Antiviral drug candidate for hepatitis B
1.00Common
Common
RG7795
- Medications
RG7795, previously called ANA773, is an orally available prodrug of isatoribine. It was developed by Anadys Pharmaceuticals, which Roche acquired in 2011. The drug candidate reached Phase II trials for hepatitis B by 2015. Its active metabolite activates TLR7, leading to secretion of endogenous type 1 interferons with antiviral activity. Development appeared to have been discontinued by 2021.
- Previous name
- ANA773
- Form
- Orally available prodrug of isatoribine
- Development status
- Appeared discontinued as of 2021
Sources and credits
Sources and credits
- Article
- RG7795 (English Wikipedia)
- Wikidata
- Q4750293
- Text
- Card text is adapted from the English Wikipedia article by an automated summary. Wikipedia content is available under CC BY-SA 4.0; see the article history for its contributors. CC BY-SA 4.0 · Article history and contributors
- Illustration
- By User:Innerstream. Public domain · File page on Wikimedia CommonsUser:Innerstream, Own workModifications: Placed on a plain background, resized and converted to WebP
- Popularity
- 0 median daily views (Wikimedia Pageviews API (all-access, user agent))
Kosmora is not affiliated with or endorsed by the Wikimedia Foundation.